{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.1","upperLimit":"87.2","value":"64.3"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"50.8","value":"21.4"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"33.9","value":"7.1"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"33.9","value":"7.1"}]}],"title":"Not done"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"BOR consists of CR (CMR/CRR), PR (PMR/PRR), SD, PD and not done. CMR/CRR and PMR/PRR are defined in Outcome Measure (OM) 1. PD is defined in OM 3. SD/no metabolic response (NMR): a score 4 (uptake moderately greater than \\[\\>\\] liver) or 5 (uptake markedly \\>liver and/ or new lesions) with no significant change in FDG uptake compared to baseline (screening), at an interim time point or end of treatment; no new sites of disease should be observed. Not done: no assessment at the time of analysis. Percentages were rounded off. Only categories with data are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"NUMBER","populationDescription":"Participants from the mITT Analysis Set in Cohort 2 were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 7.8 years","title":"Percentage of Participants With Best Objective Response (BOR) as Per Investigator Assessment Determined by Lugano Classification in Cohort 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}